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Abstract. A new ammonium acetate-assisted, convenient and efficient procedure for the synthesis of arylidene
derivatives of thiazolopyrimidine is described. The main advantages of this protocol is that it is economical,
short reaction time, commonly available chemicals, and ease of isolation of products. In addition, a new series
of thiazole-fused pyrimidines were synthesized and hydrolysis of one of its arylidene derivative studied. All the
compounds were characterized by analytical and spectroscopic methods. Further, the structure of hydrolyzed
product and two other compounds were confirmed by X-ray crystal structure analysis. The crystal structures are
stabilized by intermolecular C-H. . .O, C-H. . .N, C-H. . . π and π . . . π weak interactions. The anti-microbial
screening was done on the compounds in order to test their anti-bacterial and anti-fungal activities.
Keywords. Thiazolo[3,2−a]pyrimidines; hydrolysis of arylidene derivative; crystal structure; anti-microbial
activity.
1. Introduction
Heterocycles containing sulphur and nitrogen are of
great interest because they constitute an important class
of natural and synthetic organic molecules, many of
which exhibit useful biological activity. One such hete-
rocyclic class is thiazolopyrimidines. These have gene-
rated interest in recent years due to their biological
and pharmaceutical activities. These ring systems have
shown anti-microbial,1–4 anti-malarial,5 anti-inflam-
matory,6,7 anti-oxidant,6 anti-nociceptive7 and anti-
tubercular8 activity. In addition, they have been reported
to possess anti-tumour activity9,10 and have also shown
to possess anti-parkinsonian and anti-proliferative
properties.11
In view of all these observations, we have under-
taken the synthesis of some new derivatives of thiazolo
[3,2-a]pyrimidines. The traditional methods7,12–14 to
synthesize arylidene derivative involve the use of 1:1
mixture of acetic acid and acetic anhydride in presence
of sodium acetate. But this method is not satisfactory
with regard to the isolation of the products and also
due to the drastic reaction conditions that are employed.
To overcome this limitation, we have developed a new
protocol for the synthesis of arylidene derivative of
thiazolopyrimidines using readily available, inexpen-
sive and environment-friendly catalysts. We have made
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use of ammonium acetate under warm condition with
ethanol as a solvent medium. It is a convenient and fast
protocol, although the synthetic route followed is a con-
ventional one. However, the duration of the reaction is
very short, as it goes to completion in 10 min. This is
yet another advantage of the present protocol.
In continuation of our work with thiazolopyrimi-
dines, we report herein the synthesis of some new
derivatives and a tricyclic thiazolopyrimidine. It has
been observed that the hydrolysis of arylidene deriva-
tive of thiazolopyrimidine occurs via rupture of imine
bond under acidic condition. In this paper, the mecha-
nism for hydrolysis has been proposed. Some of these
derivatives exhibit promising anti-microbial activities.
We have presented here the crystal structure analysis of
the two derivatives. The structure analysis was under-
taken to determine the configuration and conformation
of the molecule and the orientation of the substituents
around the thiazolopyrimidine framework.
2. Experimental
2.1 Materials and methods
All the chemicals were purchased from S D Fine and
Spectrochem used as received without further purifi-
cation. Melting point apparatus was used to determine
the melting point in open capillaries and are uncorrected.
IR spectra were recorded on Nicolet Impact 400D FT-IR
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spectrophotometer using KBr pellets. Bruker 400 MHz
FT-NMR spectrometer was used to record 1H and
13C NMR in CDCl3 and DMSO-d6 with TMS as inter-
nal standard. The reactions and purity of the products
were monitored by TLC silica gel plates. Mass spec-
tra were recorded on LC-MSD-Trap-SL spectrometer
and elemental analyses were carried out using CHNS
Elimentar (Vario-micro cube).
2.2 Procedure for the synthesis of compounds 2(a–d)
A mixture of ethyl 3,5-dihydro-7-methyl-3-oxo-5-
phenyl-2H -thiazolo[3,2−a]pyrimidine-6-carboxylate
(1a/1d/1e) (10 mmol), aromatic aldehydes (10 mmol)
and catalytic amount of ammonium acetate in ethanol
(30 mL) was warmed for 5–10 min with constant stir-
ring. The reaction mixture was allowed to stand at
room temperature for 30 min. The solid thus separated
was filtered and washed with water and recrystsallized
from ethanol to afford yellow compound with good
yield 82–87%.
2.2a (2Z)-Ethyl 2-benzylidene-3,5-dihydro-7-methyl-
3-oxo-5-phenyl-2H-thiazolo[3,2-a] pyri -midine-6-car-
boxylate (2a): Yellow solid, yield 87%, M.p.: 178–
179 ◦C. IR (KBr) v cm−1:2978(CH), 1711 (C=O), 1608
(C=C), 1484 (C=N), 1169 (C-O). 1H NMR (300 MHZ,
CDCl3) δ ppm: 1.18 (t, J=7.2 Hz, 3H, CH2CH3), 2.52
(s, 3H, CH3), 4.11 (q, J=7.2 Hz, 2H, CH2CH3), 6.22
(s, 1H, C5-H), 7.26–7.45 (m, 10H, ArH). 7.73(s, 1H,
arylidene-H). 13C NMR (300 MHZ, CDCl3) δ ppm:
14.98, 23.42, 55.13, 60.35, 102.08, 108.88, 114.16,
127.41, 128.15, 129.62, 130.96, 132.43, 134.09,
144.51, 154.62, 159.62, 163.14, 165.62, 167.73.
%CHNS found (calc): C 68.30 (68.41), H 4.98 (5.13),
N 6.93 (6.82), S 7.93 (8.13).
2.2b (2Z)-Methyl 2-(3-cyanobenzylidene)-3,5-dihydro-
5-(4-hydroxyphenyl)-7-methyl-3-oxo-2H-thiazolo[3,2-
a]pyrimidine-6-carboxylate (2b): Yellow solid, yield
84%, M.p.:234–235◦C. IR (KBr) v cm−1: 2987 (CH),
1698 (C=O), 1603 (C=C), 1486 (C=N), 1231 (C-O).
1H NMR (400 MHZ, DMSO-d6) δ ppm: 2.38 (S, 3H,
CH3), 3.60 (s, 3H, OCH3), 5.96 (s, 1H, C5-H), 6.95–
7.95 (m, 9H, Ar-H), 9.58 (s, 1H, Ar-OH). 13C NMR
(400 MHZ, DMSO-d6) δ ppm: 23.31, 54.86, 61.15,
100.14, 122.96, 127.15, 128.4–137.63, 141.04, 145.78,
153.04, 164.99, 165.69, 167.47. Mass (m/z): 432.22
[M+H]+. %CHNS found (calc): C 64.03 (64.32), H
3.97 (3.76), N 9.74 (9.63), S 7.43 (7.59).
2.2c 4-((1Z)-(6-(ethoxycarbonyl)-5-(4-hydroxyphenyl)-7
-methyl-3-oxo-3H-thiazolo[3,2-a] pyrimidin-2(5H)-yli-
dene)methyl)benzoic acid (2c): Yellow solid, yield
82%, M.p.: 241–242◦C. IR (KBr) v cm−1: 2981 (CH),
1698 (C=O), 1599 (C=C), 1491 (C=N), 1215 (C-O).
1H NMR (400 MHZ, CDCl3) δ ppm: 1.18 (t, J=7.2
Hz, 3H, CH2CH3), 2.37 (s, 3H, CH3), 4.09 (q, J=7.2
Hz, 2H, CH2CH3), 6.19 (s, 1H, C5-H), 7.26–7.74 (m,
9H, Ar-H), 9.62 (s, 1H, OH), 13.10 (s, 1H, COOH).
13C NMR (400 MHZ, CDCl3) δ ppm: 14.76, 23.30,
54.86, 60.09, 100.14, 109.91, 122.96, 127.15–141.04,
145.28, 153.04, 156.04, 164.99, 165.69, 166.23,
167.47. %CHNS found (calc): C 62.06 (62.12), H 4.34
(4.52), N 6.03 (6.31), S 6.90 (6.61).
2.2d (2Z)-methyl 2-(3-fluorobenzylidene)-3,5-dihydro-
5-(4-hydroxyphenyl)-7-methyl-3-oxo-2H-thiazolo[3,2-
a]pyrimidine-6-carboxylate (2d): Yellow solid, yield
84%, M.p.: 286–287◦C. IR (KBr) v cm−1: 2976 (CH),
1701 (C=O), 1598 (C=C), 1497 (C=N), 1192 (C-O).
1H NMR (400 MHZ, CDCl3) δ ppm: 2.36 (S, 3H, CH3),
3.67 (s, 3H, OCH3), 6.02 (s, 1H, C5-H), 6.75–7.83
(m, 9H, Ar-H), 9.60 (s, 1H, OH). 13C NMR (400 MHZ,
CDCl3) δ ppm: 23.26, 55.44, 60.12, 100.14, 116.29,
122.96, 127.15, 128.4–137.63, 141.04, 145.78, 154.03,
162.31, 164.72, 165.59, 167.42. %CHNS found (calc):
C 62.25 (62.42), H 4.04 (4.06), N 6.60 (6.83), S 7.55
(7.59).
2.3 Procedure for the hydrolyzed compound 3
2.3a Method 1: Compound 1a was refluxed with
benzaldehyde in presence of ammonium acetate in
acetic acid for 5–6 h with constant stirring. The reac-
tion mixture was allowed to stand at room temperature
overnight. The solid thus separated was filtered, washed
with water and recrystallized from ethanol to afford
pale yellow crystals in good yield (82%).
2.3b Method 2: A mixture of compound 2a and cat-
alytic amount of conc. HCl in ethanol (100 mL) was
refluxed for 5–6 h with constant stirring. The reac-
tion mixture was allowed to stand room temperature
overnight. The solid thus separated was filtered, washed
with water and recrystsallized from ethanol to afford
good quality crystals (yield 80%).
2.3c (Z)-5-Benzylidenethiazolidine-2,4-dione(3): Colour-
less solid, yield 82%, M.p.: 264–265◦C. IR (KBr) v
cm−1: 3145 (NH), 3037 (CH), 1739 (SCONH),
1691 (CONH), 1606 (C=C), 1336 (C-N). 1H NMR
(300 MHZ, DMSO-d6) δ ppm: 7.42–7.58 (m, 5H, Ar-H),
7.75 (s, 1H, arylidene-H), 12.58 (s, 1H, NH), %CHNS
found (calc): C 58.52 (58.63), H 3.44 (3.23), N 6.82
(6.67), S 15.62 (15.67).
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2.4 General procedure for the synthesis compounds
4a and 4b
A mixture of ethyl 3,5-dihydro-7-methyl-3-oxo-5-
substituted phenyl-2H -thiazolo[3,2−a]pyrimidine-6-
carboxylate (5 mmol), morpholine (6 mmol), formalin
(1 mL) and acetic acid (1 mL) in methanol (20 mL) was
refluxed for 8 h (monitored by TLC). Reaction mixture
was diluted with water and extracted with chloroform
(3 × 30 mL). The combined chloroform extract was
washed with water (3 × 30 mL) and dried over anhy-
drous sodium sulfate. The solvent was removed under
vacuum and the residue was recrystallized from ben-
zene and hexane mixture to yield colorless to yellow
granules with good yield 82–87%.
2.4a (2Z)-ethyl 3,5-dihydro-7-methyl-2-(morpholino-
methyl)-3-oxo-5-phenyl-2H-thiazolo [3,2-a]pyrimidine-
6-carboxylate (4a): Pale yellow solid, yield 87%,
M.p.: 84–85◦C. IR (KBr) v cm−1: 2982 (CH), 1711
(C=O), 1613 (C=C), 1499 (C=N), 1180 (C-O).
1H NMR (400 MHZ, CDCl3) δ ppm: 1.16 (t, J=7.2
Hz, 3H, CH2CH3), 2.38 (s, 3H, CH3), 2.47 (t, J=4.5
Hz, 4H, C3, C5-H, morpholine), 3.00 (d, J=4.1 Hz,
2H, CH2-N), 3.36 (t, J=4.3 Hz, 1H, S-CH), 3.63
(t, J=4.3 Hz, 4H, C2, C6-H, morpholine), 4.07 (q,
J=7.2 Hz, 2H, CH2CH3), 5.99 (s, 1H, C5-H), 7.26–
7.36 (m, 5H, Ar-H). 13C NMR (400 MHZ, CDCl3) δ
ppm: 14.06, 22.27, 50.48, 54.11, 55.37, 57.23, 59.19,
60.51, 101.16, 117.23, 127.9–136.32, 140.07, 144.98,
155.13, 161.92, 164.29, 166.01, 167.13. %CHNS found
(calc): C 60.70 (60.49), H 6.06 (5.76), N 10.11 (10.33),
S 7.72 (7.59).
2.4b (2Z)-ethyl 3,5-dihydro-5-(3-methoxyphenyl)-7-
methyl-2-(morpholinomethyl)-3-oxo-2H-thiazolo[3,2-a]
pyrimidine-6-carboxylate (4b): Pale yellow solid,
yield 82%, M.p.: 88–89◦C. IR (KBr) v cm−1:2996
(CH), 1707 (C=O), 1601 (C=C), 1512 (C=N), 1172
(C-O). 1H NMR (400 MHZ, CDCl3) δ ppm: 1.17 (t,
J=7.2 Hz, 3H, -CH2CH3), 2.36 (s, 3H, CH3), 2.47
(t, J=4.5 Hz, 4H, C3, C5-H, morpholine), 3.08 (d,
J=4.1 Hz, 2H, CH2), 3.33 (t, J=4.3 Hz, 1H, S-CH),
3.65 (t, J=4.3 Hz, 4H, C2, C6-H, morpholine), 3.79 (s,
3H, OCH3), 4.10 (q, J=7.2 Hz, 2H, CH2CH3), 6.05
(s, 1H, C5-H), 7.13–7.41 (m, 4H, Ar-H). 13C NMR
(400 MHZ, CDCl3) δ ppm: 13.98, 22.19, 50.43,
54.17, 55.90, 57.71, 59.42, 60.18, 61.41, 100.43,
119.19, 126.36–138.50, 140.57, 144.02, 155.19,
161.92, 163.41, 165.97, 167.11. %CHNS found
(calc): C 59.31 (59.23), H 6.11 (6.37), N 9.43 (9.22),
S 7.20 (7.47).
2.5 General procedure for the synthesis of compounds
5 (a–d)
A mixture of compound 1(a–d) (10 mmol) and DMF–
DMA (5 mL) was heated under reflux for 2 h. The reac-
tion mixture was triturated with ethanol to give a solid
product that was collected by filtration and crystallized
from ethanol to give compounds 5(a–d) as deep orange
crystals with yield of 85–89%.
2.5a 2-Dimethylaminomethylene-7-methyl-3-oxo-5-
phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyrimi -dine-6-
carboxylic acid ethyl ester (5a): Orange yellow solid,
yield 87%, M.p.: 204–205◦C. IR (KBr) v cm−1:2983
(CH), 1710 (C=O), 1618 (C=C), 1490 (C=N), 1179
(C-O). 1H NMR (400 MHZ, CDCl3) δ ppm: 1.17 (t,
J=7.2 Hz, 3H, CH2CH3), 2.47 (s, 3H, CH3), 3.10 (s,
6H, 2XCH3), 4.08 (q, J=7.2 Hz, 2H, CH2CH3), 6.16
(s, 1H, C5-H), 7.19–7.39 (m, 5H, Ar-H), 7.49 (s, 1H,
=CH-NMe2). 13C NMR (400 MHz, CDCl3) δ ppm:
14.14, 23.02, 54.87, 59.99, 86.06, 106.03, 127.82-
128.34, 141.71, 145.73, 154.32, 166.05, 166.15.
%CHNS found (calc): C 61.44 (61.41), H 5.70 (5.76),
N 11.31 (11.33), S 8.63 (8.59).
2.5b 2-Dimethylaminomethylene-5-(3-methoxy-phenyl)-
7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimi-
dine-6-carboxylic acid ethyl ester (5b): Orange yel-
low solid, yield 89%, M.p.: 181–182◦C. IR (KBr) v
cm−1: 3033, 2987 (CH), 1714 (C=O), 1620 (C=C),
1499 (C=N), 1173 (C-O). 1H NMR (400 MHZ,
CDCl3) δ ppm: 1.19 (t, J=7.2 Hz, 3H, CH2CH3), 2.47
(s, 3H, CH3), 3.11 (s, 6H, 2XCH3), 3.75 (s, 3H, OCH3),
4.09 (q, J=7.2 Hz, 2H, CH2CH3), 6.15 (s, 1H, C5-H),
6.75–7.26 (m, 4H, Ar-H), 7.53 (s, 1H, =CH-NMe2).
13C NMR (400 MHz, CDCl3) δ ppm: 14.19, 22.93,
54.59, 60.06, 61.32, 86.43, 106.27, 127.85–128.54,
140.36, 141.55, 145.82, 154.41, 165.89, 166.32. Mass
(m/z): 402.3 [M+H]+. %CHNS found (calc): C 59.83
(60.12), H 5.77 (5.76), N 10.47 (10.33), S 7.99 (7.95).
2.5c 2-Dimethylaminomethylene-5-(4-methoxy-phenyl)
-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimi-
dine-6-carboxylic acid ethyl ester (5c): Orange yel-
low solid, yield 85%, M.p.: 165–167◦C. IR (KBr) v
cm−1:3035, 2996 (CH), 1711 (C=O), 1600 (C=C),
1498 (C=N), 1215 (C-O). 1H NMR (400 MHZ,
CDCl3) δ ppm: 1.18 (t, J=7.2 Hz, 3H,-CH2CH3),
2.51 (s, 3H, CH3), 3.13 (s, 6H, 2XCH3), 3.75 (s, 3H,
-OCH3), 4.09 (q, J=7.2 Hz, 2H, CH2CH3), 6.14 (s, 1H,
C5-H), 6.78–7.33 (m, 4H, Ar-H), 7.55 (s, 1H, =CH-
NMe2). 13C NMR (400 MHz, CDCl3) δ ppm: 14.03,
470 H Nagarajaiah et al.
23.21, 54.89, 59.93, 61.10, 87.33, 106.05, 127.52,
128.87, 139.59, 141.76, 145.32, 154.19, 166.27,
167.02. %CHNS found (calc): C 59.83 (60.12), H 5.77
(5.76), N 10.47 (10.33), S 7.99 (7.95).
2.5d 2-Dimethylaminomethylene-5-(4-hydroxy-phenyl)
-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimi-
dine-6-carboxylic acid ethyl ester (5d): Orange yel-
low solid, yield 87%, M.p.: 280–281◦C. IR (KBr)
v cm−1: 3321 (OH), 2979 (CH), 1712 (C=O), 1623
(C=C), 1492 (C=N), 1183 (C-O). 1H NMR (400 MHZ,
CDCl3) δ ppm: 1.21 (t, J=7.2 Hz, 3H, CH2CH3), 2.64
(s, 3H, CH3), 3.22 (s, 6H, 2XCH3), 4.12 (q, J=7.2 Hz,
2H, CH2CH3), 6.13 (s, 1H, C5-H), 6.74–7.09 (m, 4H,
Ar-H), 7.59 (s, 1H, =CH-NMe2), 9.60 (s, 1H, -OH).
13C NMR (400 MHz, CDCl3) δ ppm: 13.90, 23.01,
54.47, 60.06, 86.88, 107.03, 124.72, 127.40, 143.76,
145.19, 154.62, 165.95, 166.31. %CHNS found (calc):
C 58.90 (58.76), H 5.46 (5.59), N 10.85 (10.63), S 8.28
(8.31).
2.6 General procedure for the synthesis of compounds
6a and 6b
A mixture of 2-dimethylaminomethylene-7-methyl-
3-oxo-5-substituted phenyl-2,3-dihydro-5H -thiazolo
[3,2−a]pyrimidine-6-carboxylic acid ethyl ester
(5 mmol), 2-amino benzoic acid (5 mmol) and acetic
acid (1 mL) in methanol (30 mL) was refluxed for
8 h (monitored by TLC). The excess methanol was
removed under reduced pressure. The compound was
diluted with water. The solid thus separated was filtered
and dried to give yellow compound with 60–63% yield.
2.6a 2-((1Z)-(6-(ethoxycarbonyl)-7-methyl-3-oxo-5-
phenyl-3H-thiazolo[3,2-a]pyrimidin-2 (5H)-ylidene)methy
lamino)benzoic acid (6a): Yellow solid, yield 60%,
M.p.:244–245◦C. IR (KBr) v cm−1: 3340 (OH),
2994(CH), 1712 (ester C=O), 1690 (COOH), 1510
(C=C), 1042(C-O). 1H NMR (400 MHZ, DMSO-d6) δ
ppm: 1.10 (t, J=7.2 Hz, 3H, CH2CH3), 2.21 (s,3H,
CH3), 3.99 (q, J=7.2 Hz, 2H, CH2), 5.72 (s, 1H, C5-H),
6.63–8.03(m, 8H, Ar-H), 9.87 (d,1H, NH), 11.83(s, 1H,
COOH). 13C NMR (400 MHZ, DMSO-d6) δ ppm:14.02,
17.70, 53.72, 59.14, 112.10, 112.35, 114.44–132.25,
145.41, 146.32, 159.61, 167.29. %CHNS found (calc):
C 62.19 (62.34), H 4.57 (4.53), N 9.07 (8.88), S 6.92
(6.97).
2.6b 2-(-(6-(ethoxycarbonyl)-5-(3-methoxyphenyl)-7-
methyl-3-oxo-3H-thiazolo[3,2-a]pyrimi -din-2(5H)-yli-
dene)methylamino)benzoic acid (6b): Yellow solid,
yield 63%, M.p.:220–221◦C. IR (KBr) v cm−1:3342
(-OH), 2987 (CH), 1710 (ester C=O), 1691 (COOH),
1503 (C=C), 1052 (C-O). 1H NMR (400 MHZ, DMSO-
d6) δ ppm: 1.11 (t, J=7.2 Hz, 3H, CH2CH3), 2.23
(s,3H, CH3), 3.79 (s,3H, OCH3), 3.99 (q, J=7.2 Hz,
2H, CH2), 5.73 (s, 1H, C5-H), 6.76–8.05(m, 9H, Ar-H),
9.88 (d, 1H, NH), 11.85 (s, 1H, -COOH). 13C NMR
(400 MHZ, DMSO-d6) δ ppm:14.23, 17.68, 53.70,
55.25, 59.15, 112.10, 112.35, 115.26–134.39, 144.54,
146.30, 159.60, 167.20. %CHNS found (calc): C 60.84
(60.99), H 4.70 (4.63), N 8.51 (8.67), S 6.50 (6.38).
2.7 General procedure for the synthesis of compounds
7 (a–f)
To a solution of 5a/5b (5 mmol) in ethanol (30 mL) sec-
ondary amines like morpholine, piperidine and pyrro-
lidine (5 mmol) was added and then refluxed for sev-
eral hours. Completion of the reaction was monitored
by TLC. The solid separated was filtered and dried to
get the desired product.
2.7a 7-Methyl-2-morpholin-4-ylmethylene-3-oxo-5-phe-
nyl-2,3-dihydro-5H-thiazolo[3,2-a] pyrimidine-6-car-
boxylic acid ethyl ester (7a): Pale orange yel-
low solid, yield 80%, M.p.:221–222◦C. IR (KBr) v
cm−1:2982 (CH), 1705 (C=O), 1612 (C=C), 1502
(C=N), 1192 (C-O). 1H NMR (400 MHZ, CDCl3) δ
ppm: 1.17 (t, J=7.2 Hz, 3H, CH2CH3), 2.50 (s, 3H,
CH3), 3.45 (t, J=4.8 Hz, 4H, CH2CH2), 3.73 (t, J=4.8
Hz, 4H, CH2CH2), 4.09 (q, J=7.2 Hz, 2H, CH2CH3),
6.17 (s, 1H, C5-H), 7.23–7.40 (m, 5H, Ar-H), 7.49 (s,
1H,=CH-N(CH2)2). 13C NMR (400 MHZ, CDCl3) δ
ppm: 14.16, 23.02, 55.57, 57.03, 59.89, 60.15, 100.18,
117.54, 125.79–137.27, 140.04, 144.56, 155.29,
161.09, 164.61, 166.26, 167.01. %CHNS found (calc):
C 61.00 (61.10), H 5.61 (5.66), N 10.16 (10.31), S 7.75
(7.93).
2.7b 5-(3-Methoxy-phenyl)-7-methyl-2-morpholin-4-
ylmethylene-3-oxo-2,3-dihydro-5H-thia -zolo[3,2-a]py-
rimidine-6-carboxylic acid ethyl ester (7b): Pale
orange yellow solid, yield 78%, M.p.:214–215◦C. IR
(KBr) v cm−1: 3037, 2956 (CH), 1703 (C=O), 1610
(C=C), 1501 (C=N), 1198 (C-O). 1H NMR (400 MHZ,
CDCl3) δ ppm: 1.18 (t, J=7.2 Hz, 3H, CH2CH3), 2.51
(s, 3H, CH3), 3.43 (t, J=4.8 Hz, 4H, CH2CH2), 3.73
(t, J=4.8 Hz, 4H, CH2CH2), 4.05 (q, J=7.2 Hz, 2H,
CH2CH3), 6.12 (s, 1H, C5-H), 7.27–7.64 (m, 4H, Ar-
H), 7.51 (s, 1H, =CH-N(CH2)2). 13C NMR (400 MHZ,
CDCl3) δ ppm: 14.01, 23.12, 55.47, 57.17, 58.03,
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59.67, 60.18, 100.04, 119.21, 125.63–137.37, 140.16,
144.37, 154.48, 160.59, 164.16, 166.66, 167.13.
%CHNS found (calc): C 59.58 (59.62), H 9.47 (9.71),
N 9.47 (9.38), S 7.23 (7.15).
2.7c 7-Methyl-3-oxo-5-phenyl-2-piperidin-1-ylmethy-
lene-2,3-dihydro-5H-thiazolo[3,2-a] pyrimidine-6-car-
boxylic acid ethyl ester (7c): Pale orange red solid,
yield 76%, M.p.:242–243◦C. IR (KBr) v cm−1: 2974
(CH), 1701 (C=O), 1605 (C=C), 1495 (C=N), 1188
(C-O). 1H NMR (400 MHZ, CDCl3) δ ppm: 1.28 (t,
J=7.2 Hz, 3H, CH2CH3), 1.64 (m,6H, C3, C4, C5-H,
piperidine), 2.51 (s, 3H, CH3), 3.42(m,4H, C2, C6-H,
piperidine), 4.09 (q, J=7.2 Hz, 2H, CH2CH3), 6.11
(s, 1H, C5-H), 6.93–7.25 (m, 5H, Ar-H), 7.52 (s, 1H,
=CH-N(CH2)2). 13C NMR (400 MHZ, CDCl3) δ ppm:
14.16, 23.02, 24.42, 26.31, 54.49, 59.84, 60.30, 100.19,
118.03, 123.79–134.27, 140.44, 144.01, 155.57,
160.69, 164.72, 166.32, 167.11. %CHNS found (calc):
C 64.21 (64.23), H 6.12 (6.31), N 10.21 (10.37), S 7.79
(7.61).
2.7d 5-(3-Methoxy-phenyl)-7-methyl-3-oxo-2-piperi-
din-1-ylmethylene-2,3-dihydro-5H-thia-zolo[3,2-a]py-
rimidine-6-carboxylic acid ethyl ester (7d): Pale
orange red solid, yield 73%, M.p.:237–238◦C. IR
(KBr) v cm−1: 2945 (CH), 1700 (C=O), 1611
(C=C), 1493 (C=N), 1196 (C-O). 1H NMR (400
MHZ, CDCl3) δ ppm: 1.19 (t, J=7.2 Hz, 3H,
CH2CH3), 1.66 (m,6H, C3, C4, C5-H, piperidine), 2.49
(s, 3H, CH3), 3.41(m,4H, C2, C6-H, piperidine), 3.76
(s, 3H, OCH3), 4.10 (q, J=7.2 Hz, 2H, CH2CH3), 6.16
(s, 1H, C5-H), 6.76–7.26 (m, 4H, Ar-H), 7.56
(s, 1H, =CH-N(CH2)2). 13 C NMR (400 MHZ, CDCl3)
δ ppm: 14.10, 22.96, 24.12, 26.54, 55.55, 57.42, 59.91,
61.10, 101.12, 117.53, 127.12–136.19, 141.19, 144.23,
155.54, 161.03, 163.91, 166.60, 167.33. Mass (m/z):
441.8 [M]+. %CHNS found (calc): C 62.56 (62.39), H
6.16 (5.97), N 9.52 (9.38), S 7.26 (7.19).
2.7e Ethyl 3,5-dihydro-7-methyl-3-oxo-5-phenyl-2-
((pyrrolidin-1-yl)methylene)-2H-thiazolo [3,2-a]pyri-
midine-6-carboxylate (7e): Pale orange yellow solid,
yield 75%, M.p.:262–263◦C. IR (KBr) v cm−1: IR
(KBr νmax, cm−1): 3052, 2976 (CH), 1707 (C=O), 1620
(C=C), 1502 (C=N), 1190 (C-O). 1H NMR (400 MHZ,
CDCl3) δ ppm: 1.22 (t, J=7.2 Hz, 3H, CH2CH3),
1.78(m, 4H, C3, C4-H, pyrrolidine), 2.36 (s, 3H, CH3),
2.65 (m, C2, C5-H, pyrrolidine), 4.09 (q, J=7.2 Hz, 2H,
CH2CH3), 6.07 (s, 1H, C5-H), 7.19–7.32 (m, 5H, Ar-
H), 7.52 (s, 1H, =CH-N(CH2)2). 13C NMR (400 MHZ,
CDCl3) δ ppm: 14.03, 23.10, 25.31, 54.43, 59.86,
61.01, 100.17, 118.33, 123.19–135.42, 139.94, 144.21,
155.37, 160.51, 164.62, 166.17, 167.02. %CHNS
found (calc): C 63.45 (63.23), H 5.83 (5.67), N 10.57
(10.61), S 8.07 (7.97).
2.7f Ethyl 3,5-dihydro-5-(3-methoxyphenyl)-7-methyl-
3-oxo-2-((pyrrolidin-1-yl)methylene)-2H-thiazolo[3,2-a]
pyrimidine-6-carboxylate (7f): Pale orange yellow
solid, yield 73%, M.p.: 254–255◦C. IR (KBr) v cm−1:
3048, 2977 (CH), 1703 (C=O), 1618 (C=C), 1506
(C=N), 1197 (C-O). 1H NMR (400 MHZ, CDCl3) δ
ppm: 1.24 (t, J=7.2 Hz, 3H, CH2CH3), 1.78 (m, 4H,
C3, C4-H, pyrrolidine), 2.64 (m, C2, C5-H, pyrrolidine),
2.34 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 4.11 (q, J=7.2
Hz, 2H, CH2CH3), 6.02 (s, 1H, C5-H), 6.78–7.29 (m,
4H, Ar-H), 7.53 (s, 1H, =CH-N(CH2)2). 13C NMR
(400 MHZ, CDCl3) δ ppm: 14.03, 22.99, 25.51, 55.53,
57.52, 59.71, 61.23, 100.96, 118.01, 129.36–135.49,
141.02, 144.19, 155.37, 161.29, 163.71, 166.32,
167.18. %CHNS found (calc): C 61.81 (61.67), H 5.89
(5.71), N 9.83 (9.92), S 7.50 (7.41).
2.8 Procedure for the synthesis of tricyclic
thiazolopyrimidine
2.8a Procedure for the synthesis of ethyl 3-amino-2-
cyano-5-(3-methoxyphenyl)-7-methyl-5H-thiazolo[3,2-
a]pyrimidine-6-carboxylate (9): To a warm solution
of KOH (10 mmol) and pyrimidine derivative (8)
(10 mmol) in ethanol (30 mL), bromomalononitrile
(11 mmol) was added dropwise with constant stirring.
The reaction mixture was stirred for 2 h. The solution
was allowed to stand at room temperature for some
time and the solid product precipitated. The precipitate
was filtered and recrystallized from ethanol.
Yellow solid, yield 88%, M.p.:238–239◦C. IR (KBr)
v cm−1: 3373, 3329 (NH2) 2931 (CH), 2189 (C≡N)
1703 (C=O), 1655 (C=C), 1566 (C=N), 1195 (C-O).
1H NMR (400 MHZ, CDCl3) δ ppm: 1.25 (t, J = 7.1 Hz,
3H, CH2CH3), 2.35 (s, 3H, CH3), 3.78(s, 3H, OCH3),
4.12 (q, J = 7.0 Hz, 2H, CH2CH3), 4.75 (s, 2H, NH2),
6.06 (s, 1H, C5-H), 6.84–6.94 (m, 4H, Ar-H). 13C NMR
(400 MHZ, CDCl3) δ ppm:14.09, 23.06, 54.87, 60.06,
90.43, 102.32, 113.76, 118.42, 129.63, 132.63, 143.19,
155.35, 157.99, 163.16, 164.09, 165.23. %CHNS found
(calc): C 58.36 (58.62), H 4.90 (5.06), N 15.12 (15.13),
S 8.66 (8.59).
2.8b Procedure for the synthesis 2-cyano-3-(1-ethoxy-
ethylideneamino)-5-(3-methoxy-phenyl)-7-methyl-5H-
thiazolo[3,2-a]pyrimidine-6-carboxylic acid ethyl ester
(10): A mixture of 9 (1.85 g, 5 mmol) and triethy-
lorthoacetate (2 mL) was heated under reflux in acetic
anhydride for 6 h, excess triethylorthoacetate and acetic
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anhydride was removed. The residue was treated with
petroleum ether. The solid thus separated was filtered,
washed and recrystallized with petroleum ether to
afford light greenish yellow crystals.
Yellow green solid, yield 83%, M.p.:110–111◦C.
IR (KBr) v cm−1: 2977, 2935 (CH), 2224 (C≡N),
1703 (C=O), 1616 (C=C), 1541 (C=N), 1184 (C-O);
1H NMR (400 MHZ, CDCl3) δ ppm: 1.21 (t, J = 7.1
Hz, 3H, CH2CH3), 1.36 (t, J = 7.1 Hz, 3H, CH2CH3),
1.43(s, 3H, CH3), 2.00 (s, 3H, CH3), 2.36 (s, 3H,
CH3), 3.73(s, 3H, OCH3), 4.08 (q, J = 7.0 Hz, 2H,
CH2CH3), 4.28 (q, J = 7.0 Hz, 2H, CH2), 5.94 (s, 1H,
C5-H), 6.76–7.23 (m, 4H, Ar-H). 13C NMR (400 MHZ,
CDCl3) δ ppm:14.11, 23.14, 25.08, 54.08, 54.89, 59.46,
90.48, 102.30, 112.89, 113.05, 118.68, 129.63, 143.17,
155.35, 158.97, 159.55, 163.23, 164.17, 165.46.
%CHNS found (calc): C 58.96 (58.72), H 5.16 (5.33),
N 11.96 (12.01), S 6.84 (7.03).
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2.8c Procedure for the synthesis 7-amino-8-imino-
4-(3-methoxy-phenyl)-2,6-dimethyl-7,8-dihydro-4H-9-
thia-1,4a,5,7-tetraaza-fluorene-3-carboxylic acid ethyl
ester (11): A mixture of 10 (2.2 g, 5 mmol) and
hydrazine hydrate (7 mL) was stirred at room tempera-
ture for 2 h and then diluted with ethanol (20 mL). The
resulting fine solid suspension was filtered, washed
with ethanol and purified by recrystallization from
ethanol-dioxane mixture to afford analytically (TLC)
pure pale yellow granules.
Yellow solid, yield 62%, M.p.:225–226◦C. IR (KBr)
v cm−1: 3361 (NH), 3232, 3190 (NH2), 2923 (CH),
1697 (C=O), 1652 (C=C), 1492 (C=N), 1230 (C-O).
1H NMR (400 MHZ, DMSO-d6) δ ppm: 1.15 (t, J=7.2
Hz, 3H, CH2CH3), 2.29 (s, 3H, CH3), 2.33 (s, 3H,
CH3), 3.68 (s, 3H, OCH3), 4.06 (q, J=7.2 Hz, 2H,
CH2CH3), 4.81 (s, 2H, NH2), 6.42 (s, 1H, C5-H of
thiazolopyrimidine), 6.78–7.21 (m, 4H, Ar-H), 8.97
(s, 1H, = NH). 13C NMR (400 MHZ, DMSO-d6) δ ppm:
14.11, 23.14, 25.08, 54.08, 54.89, 59.46, 90.48, 102.30,
112.89, 113.05, 118.68, 129.63, 143.17, 155.35,
158.97, 159.55, 163.23, 164.17, 165.46. %CHNS found
(calc): C 56.32 (56.42), H 5.20 (4.99), N 19.70 (19.83),
S 7.52 (7.59).
2.9 X-ray diffraction analysis
Good quality single crystals of compounds 3, 5b and
7a were obtained by slow evaporation of ethanol.
The X-ray diffraction data, for the compounds 3,
5b and 7a were collected on a Bruker Smart CCD
Area Detector System using MoKα (0.71073 Å) radi-
ation. The data were reduced using SAINT-Plus.15
The structure was solved by Direct methods using
SHELXS9716 and refined by difference Fourier synthe-
ses using SHELXL97.16 The positions and anisotropic
displacement parameters of all non-hydrogen atoms
were included in the full-matrix least-square refine-
ment using SHELXL9716 and the refinement proce-
dures were carried out until convergence was reached.
The H atoms were placed at calculated positions in the
riding model approximation, their temperature factors
were set to 1.2 times those of the equivalent isotropic
temperature factors of the parent atoms. All other
non-H atoms were refined anisotropically. Molecu-
lar diagrams were generated using ORTEP.17 The
mean plane calculation was done using the program
PARST.18
2.10 Anti-microbial activity
Anti-microbial activities of the synthesized compounds
2d, 4a, 5a, 5b, 6a, 7a, 7d, 9 and 10 were screened
against the two standard bacterial strains Staphylo-
coccus aureus, E.coli and two standard fungal strains
Aspergillus niger, Penicillium chrysogenum by Agar
diffusion method with 3 different concentrations (0.5,
1.0, 2.0 mg/mL).19,20
For anti-bacterial activity test, media used was pep-
tone 10 g, NaCl 10 g and yeast extract 5 g, agar 20 g
in 1000 mL distilled water. Initially, the stock cultures
of bacteria were revived by inoculating in broth media
and grown at 37◦C for 18 h. The agar plates of the
above media were prepared and wells were made in the
plate. Each plate was inoculated with 18 h old cultures
(100 μL, 10−4CFU) and spread evenly on the plate.
After 20 min, the wells were filled with compound
at different concentrations. The control wells with
Gentamycin were also prepared. All the plates were
incubated at 37◦C for 24 h and the diameter of inhibition
zone were noted.
For anti-fungal activities media used was Czapek-
Dox Agar: Composition (g/L) Sucrose-30.0; Sodium
nitrate-2.0; K2HPO4-1.0, MgSO4. 7H2O-0.5; KCl-0.5;
FeSO4-0.01; Agar-20: Initially, the stock cultures
offungi were revived by inoculating in broth media and
grown at 27◦C for 48 h.
The agar plates of the above media were prepared
and wells were made in the plate. Each plate was
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inoculated with 48 h old cultures (100 μL, 104 CFU)
and spread evenly on the plate. After 20 min, the wells
were filled with different concentrations of samples.
The control wells were filled with antibiotic. All the
plates were incubated at 27◦C for 72 h and the diam-
eter of inhibition zone were noted. The results of the
anti-microbial activities are shown in table 3.
3. Result and Discussion
3.1 Chemistry
Compounds were synthesized by following procedure
depicted in the schemes 1, 2, 3 and 4. The starting
materials 7-methyl-3-oxo-5-(substituted phenyl)-2,3-
dihydro-5H -thiazolo[3,2-a]pyrimidine-6-carboxylic acid
N
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Scheme 3. Synthesis of dimethyl amino-methylene derivatives of thiazolopyrimidines.
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ethyl esters 1(a–e) were prepared by treating 6-methyl-
4-(substituted phenyl)-2-thioxo-1,2,3,4-tetrahydro-py-
rimidine-5-carboxylic acid ethyl esters with chloro acetic
acidin dioxane under reflux condition. These active
methylene compounds 1a, 1d and 1e were further
allowed to react with substituted aromatic aldehydes
in presence of ammonium acetate to givearylidene
derivatives of thiazolopyrimidine. The 1H NMR spec-
tra of compounds 2(a–d) indicate the absence of sig-
nals for the CH2 proton around δ 3.7–3.9 ppm and addi-
tional signals in the aromatic region. Acid hydrolysis of
arylidene derivative 2a leads to the formation of
thiazolid-2,4-one (3) via the rupture of endocyclic C=N
bond in pyrimidine ring by method 1. The hydrolyzed
component (3) was also obtained by an alternative
method 2, which involves in situ condensation followed
by hydrolysis (scheme 1).
Compounds 1a and 1b undergo Mannich reaction
with different secondary amines yielding compounds
4a and 4b. Further treatment of compounds 1(a–d)
with dimethylformamide–dimethylacetal (DMF-DMA)
under reflux condition gave 2-dimethylaminomethylene-
7-methyl-3-oxo-5-(substituted phenyl)-2,3-dihydro-5H -
thiazolo[3,2-a]pyrimidine-6-carboxylic acid ethyl esters
5 (a–d). In order to confirm the spectral data, one of
the derivative 5b was subjected to single crystal X-ray
diffraction technique. Crystal structure of compound 5b
showed that the product is Z-isomer. Treatment of com-
pounds 5a and 5b with 2-amino benzoic acid gave the
corresponding secondary amine derivative. Reaction of
compounds 5a and 5b with secondary amines likes
morpholine, piperidine or pyrrolidine taken in ethanol,
on refluxing gave corresponding tertiaryamines 7 (a–f)
(scheme 2). In addition to spectral technique, one of
the tertiary amine was subjected to single crystal X-ray
diffraction technique. Crystal structure of compound 7a
showed the morpholine ring adopts chair conformation.
Compound 8 was synthesized from well-known
Biginelli one pot cyclo-condensation reaction.21 The
reaction of dihydropyrimidine (8) with bromomalonon-
itrile in presence of strong base resulted in the forma-
tion of compound 9. Product was confirmed by using
spectral techniques. In the IR spectrum of compound
9 there is an appearance of sharp peak at 2189 cm−1
characteristic of nitrile group and two sharp peaks at
3300–3150 cm−1 correspond to -NH2 group and in the
1H NMR spectrum, appearance of signal at δ 4.75 ppm
correspond to -NH2 confirming ring closure. Compound
Table 1. Crystal data and refinement parameters for compounds 3, 5b and 7a.
3 5b 7a
Formula C10H7NO2S C20H23N3O4S C21H23N3O4S
M 205.23 401.47 413.48
T /K 296(2) 296(2) 296(2)
Crystal system Monoclinic Monoclinic Monoclinic
Space group P21/c P21/c P21/c
a/Å´ 9.4365(6) 15.4787(17) 12.3736(13)
b/Å´ 11.5294(8) 9.6946(11) 12.2454(13)
c/Å´ 8.1876(6) 13.0224(14) 13.0093(13)
β/(o) 95.5990(10) 90.836(2) 99.458(2)
V /Å´3 886.54(11) 1953.9(4) 1944.4(3)
Z, dcalcd/(g cm−3) 4, 1.538 4, 1.365 4, 1.413
μ/mm−1 0.332 0.198 0.201
F (000) 424 848 872
θ range/(◦) 2.80 to 25.00 1.32 to 27.00 1.67 to 27.00
Index ranges −11 <= h <= 11 −15 <= h <= 19 −13 <= h <= 15
−13 <= k <= 13 −12 <= k <= 12 −14 <= k <= 15
−9 <= l <= 7 −15 <= l <= 16 −16 <= l <= 8
Reflections collected 4506 11280 11413
Independent 1554 4209 4197
reflections [Rint = 0.0214] [Rint = 0.0386] [Rint = 0.0356]
Completeness 99.4% 98.5 % 98.8%
Data/restraints/parameters 1554 /0/127 4209/0/258 4197/0/264
Goodness-of-fit onF 2 0.940 1.499 0.949
R1, wR2 [I > 2σ(I)] 0.0347, 0.0998 0.0671, 0.1763 0.0619, 0.1644
R1, wR2 (all data) 0.0369, 0.1059 0.0966, 0.2502 0.0865, 0.2418
Largest diff. peak, 0.266, −0.363 0.947, −0.774 0.751, −0.761
hole/(e A−3)
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9 and triethylorthoacetate was refluxed in acetic anhy-
dride to give compound 10. IR spectrum shows the
absence of peaks around 3300–3150 cm−1 confir-
ming the absence of -NH2 group and from the 1H NMR
spectrum appearance of signals at δ 1.36, 1.45
and 4.28 ppm corresponds to additional -CH3,-CH3
and -CH2 groups respectively. Further treatment of
compound 10 with hydrazine hydrate in ethanol
gave tricyclic thiazolopyrimidine 11. The ring system
obtained was confirmed by IR spectrum. The absence
of peak at 2189 cm−1 indicates that there is nonitrile
group, the appearance of peak at 3361 and peaks at
3232 and 3190 cm−1 corresponds to -NH and -NH2
group.
3.2 Crystallography
The details of crystal data and refinements are given
in table 1 for the compounds 3, 5b and 7a. Tables
2a and 2b give respective hydrogen bond interactions.
The ORTEP view of the molecule with atomic labeling
(thermal ellipsoids drawn at 50% probability) of 3, 5b
and 7a are shown in figures 1, 2a and 2b respectively.
Figures 3a, 3b and 3c show the packing of molecules in
the crystal structure.
Compounds 5b and 7a crystallize in the monoclinic
space group containing one molecule each in the asym-
metric unit. Both the compounds have almost simi-
lar substituents at C2, C3, C5, C6 and C7. In com-
pounds 5b and 7a, the aryl ring at C5 is positioned
axially to the pyrimidine ring22 with a dihedral angle
of 89.88(8) and 89.66(8)◦ respectively. Aryl ring in
both the compounds is projecting away from the plane
of the thiazolopyrimidine ring. The ethyl carboxylate
group at C6 in compound 7a is planar with respect to
the thiazolopyrimidine ring whereas in compound 5b
Figure 1. ORTEP diagram for the hydrolyzed compound 3.
(a)
(b)
Figure 2. (a) ORTEP view of compound 5b, showing 50%
probability ellipsoids and the atom numbering scheme. (b)
ORTEP view of compound 7a, showing 50% probability
ellipsoids and the atom numbering scheme.
it slightly deviates from the mean plane of thiazolopy-
rimidine with dihedral angle of 17.77(8)◦ this may be
attributed to the presence of bulky group at C5. The
centralpyrimidine ring in compounds 5b and 7a adopt
twist boat conformation22 due to the deviation of C5
and N2 atom from the mean plane C6/C7/C9/N1 consti-
tuting ring by -0.295/-0.297(3)and -0.052/-0.066(3) Å´
respectively. The two values separated by ‘/’ correspond
to two different compounds i.e. 5b and 7a. In com-
pound 5b, dimethylaminomethylene group adopts Z
configuration. The substituted morpholine ring at C17
of compound 7a adopts chair conformation with the
atoms N3 and O4 displaced from the mean plane of the
remaining ring atoms (C18/C19/C20/C21) by 0.6863
(2) and −0.5735 (2) Å´, respectively.
The crystal structure of the compound 5b is sta-
bilized by C-H. . .O and C-H. . .N interactions. There
are two types of C-H. . .O interactions, the former C8-
H8A. . .O4 interaction running along crystallographic
‘b’ axis, whereas the later C12-H12. . .O1 interaction
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running along crystallographic ‘c’ axis. Both resulted
in two dimensional networks. The C-H. . .N interaction
generates bifurcated bonds from two donors, C17 and
C18, to the same acceptor N2 along ‘c’ axis. The crystal
structure is further stabilized by C4-H4B. . .Cg1 (Cg1
is the centroid of aryl ring C11–C16) interaction with a
distance of 2.842 Å´ (table 2a).
The crystal structure of the compound 7a is also sta-
bilized by C-H. . .O and C-H. . .N interactions. As in
the case of compound 5b there are two types of C-
H. . .O interactions. Here one of the C-H. . .O interac-
tion generates bifurcated bonds from two donors, C4
and C14, to the same acceptor O4 along ‘a’ axis. The
other two interactions C-H. . .O and C-H. . .N are resul-
ting in a helical pattern running along the ‘b’ axis
(figure 3c). The crystal structure is also stabilized
by C19-H19B. . .Cg2 (Cg2 is the centroid of aryl
ring C11–C16) interaction with a distance of 2.940 Å´
Figure 3. (a) Packing of the compound 5b showing intermolecular C-H. . .O and C-H. . .N interactions. (b) Packing
of the compound 7a showing intermolecular bifurcated C-H. . .O interactions. (c) Packing of the compound 7a showing
intermolecular C-H. . .O and C-H. . .N interactions.
Table 2a. C-H. . . π interaction and possible hydrogen bond distances and angles (Å, ◦) for compound 5b (D-donor; A-
acceptor; H-hydrogen).
D—H· · · A D—H H· · · A D· · · A D—H· · · A
C8-H8A. . .O4i 0.970 2.428 3.302(4) 150
C12-H12. . .O1ii 0.930 2.537 3.288(4) 138
C18-H18A. . .N2iii 0.970 2.725 3.639(5) 159
C17-H17. . .N2iv 0.930 2.554 3.470(4) 168
C4-H4B. . .C vg1 0.960 2.842 3.733(4) 155
Symmetry code: (i) x,+y − 1,+z (ii) x,−y + 1/2,+z + 1/2 (iii) x,−y + 1/2,+z − 1/2 (iv) x,−y + 1/2,+z − 1/2 (v)
x, 1/2 − y, z − 1/2
Table 2b. C-H. . . π interaction and possible hydrogen bond distances and angles (Å, ◦) for compound 7a (D-donor; A-
acceptor; H-hydrogen).
D—H· · ·A D—H H· · · A D· · · A D—H· · · A
C21–H21A...O1i 0.970 2.670 3.499(4) 144
C14 -H14A...O4ii 0.930 2.566 3.477(4) 166
C18-H18B...N2iii 0.970 2.684 3.653(4) 177
C4-H4A...O4iii 0.960 2.577 3.534(4) 174
C19-H19B. . .C ivg2 0.969 2.940 3.715(4) 137
Symmetry code: (i) −x + 1,+y − 1/2,−z + 1/2 (ii) x + 1,+y,+z (iii) −x + 1,+y + 1/2,−z + 1/2 (iv) 1 − x, 1 − y, 1 − z
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Table 3. Inhibition zone diameter (mm) of synthesized compounds against testedbacterial strains by Agar diffusion method.
Bacteria Fungi
Compounds E.coli S. aureus A. niger P. crysogenium
Sample concentration 0.5 mg 1 mg 2 mg 0.5 mg 1 mg 2 mg 0.5 mg 1 mg 2 mg 0.5 mg 1 mg 2 mg
2d - - - - - - - - - - - -
4a 7 10 17 4 5 7 - - - - - -
5a - - - - - - - - - - - -
5b - - - - - - - - - - - -
6a 0 3 5 0 2 3 - - - - - -
7a - - - - - - 0 1 3 - - -
7d - - - - - - - - - - - -
9 - - - - - - - - - - - -
10 - - - 0 2 5 - - - - - -
200 μg 400 μg 800 μg 200 μg 400 μg 800 μg 200 μg 400 μg 800 μg 200 μg 400 μg 800 μg
Gentamicin 2.6 2.8 3.1 2.5 2.7 3.4 ND ND ND ND ND ND
Amphotericin ND ND ND ND ND ND 3 5 7 0 3 5
Note: “-” Not Active, “ND” – Not Determined.
(table 2b). Finally, supramolecular assembly is further
consolidated by π−π stacking interactions between
the thiazolopyrimidine rings. This interaction is not
observed in the case of compound 5b.
3.3 Anti-microbial evaluation
The anti-microbial screening was done using agar dif-
fusion method using different strains of bacteria and
fungi. The results with the test compounds 2d, 4a, 5a,
5b, 6a, 7a, 7d, 9 and 10 reveal that only few compounds
exhibit antimicrobial activity. Gentamicin and Ampho-
tericin were used as reference to evaluate the potency of
tested compounds. Compounds 6a, 7a and 10 showed
moderate anti-microbial activity, while compound 4a
showed very good activity even at low concentration.
Compounds 2d, 5a, 5b, 7d and 9 did not show any
activity against the tested microorganisms. The result of
anti-microbial activity is tabulated in table 3.
4. Conclusion
This work reports the synthesis of a new series of thia-
zolopyrimidines. We have developed a new and conve-
nient synthetic method for the preparation of arylidene
derivatives of thiazolopyrimidine. During our studies
with thiazolopyrimidines, we have also noticed that
hydrolysis of arylidene derivative of thiazolopyrimi-
dine via rupture of endocyclic C=N bonds in pyrimi-
dine ring under acidic condition gives the same prod-
uct as that obtained by in situ condensation followed
by hydrolysis (scheme 1, method 1), for which a
mechanism has been proposed. The structures of the
products were confirmed by spectral techniques. In
addition, crystal structures of two of the derivatives that
yielded good quality crystals were verified by single
crystal X-ray diffraction. Crystal structures reveal that
compounds 5b and 7a are Z-isomers. Crystal struc-
ture of compound 7a showed the substituted morpho-
line ring adopts chair conformation. In both the deriva-
tives, the ester at C6 adopts cis configuration with
respect to C6-C7 double bond, which is a prerequi-
site for the molecule to exhibit calcium channel mod-
ulatory activity.23 On screening all the compounds,
only compounds 4a, 6a, 7a, 9 and 10 exhibited good
anti-microbial activities at very low concentration of
0.5–2.0 mg/mL against Aspergillus niger, Penicillium
chrysogenum, Staphylococcus aureus and Escherichia
coli. using Gentamicin and Amphotericin as standards.
Supplementary Information
The CIF files are deposited at the Cambridge Crystal-
lographic Data Centre. The deposition number of com-
pounds 3, 5b and 7a are CCDC-966410, CCDC-975896
and CCDC-975899, respectively.
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